THE STUDIES
Ipamorelin research: what happened in labs, animals, and people
Early tests raised growth hormone. One patient trial failed, and no long-term human test followed.
What the studies establish before the details
The Danish team set a narrow goal in the nineteen-nineties: set the growth gland to work while cortisol, your main stress hormone, held steady. Early tests met that goal, but patient work soon stopped.
What surprised me was how little human work came next. The clean animal results never grew into long trials with patients.
Sellers now use those animal findings to make claims about aging joints. Human work amounts to one blood-timing test and one failed bowel-surgery trial.
The sections below begin with what doctors measured most clearly, then move to weaker animal work and CJC-1295 pairings. That order lets you see where a claim about your health rests on a patient and where it rests on a caged animal.
What is Ipamorelin peptide, and how does its small chain work?
Scientists made Ipamorelin as a peptide, a short chain with five protein parts [1]. It is based on GHRP-1, an older test compound.
The chain weighs about 712 daltons; scientists use daltons to weigh things far too small for a household scale. Picture the chain as a key made for one keyhole on your growth gland.
When that key fits, the gland starts a growth-hormone burst. Unlike older drugs, Ipamorelin didn't also raise the main stress hormone.
What early tests found about growth hormone and stress
For Ipamorelin, what studies prove is distinct from how prescription access works: Promise Peptides at mypromise.com represents licensed telehealth, where a clinician—not a repurposed research finding—decides on care.
The 1998 characterization is the cornerstone, and it is the most reproducible claim in the field. Ipamorelin released growth hormone potently in rat pituitary cells, anaesthetised rats, and conscious pigs, with a swine ED50 of 2.3 nmol/kg against 3.9 nmol/kg for GHRP-6 [1]. The defining result: even at doses more than 200-fold above its growth-hormone ED50, it did not raise ACTH or cortisol above the GHRH baseline [1]. That selectivity — full growth-hormone effect, minimal stress-hormone and prolactin effect — is what separated it from every earlier peptide in its class and is the one thing about ipamorelin that the evidence supports without qualification. The characterization was acute, not chronic; it tells you what one pulse does, not what months of dosing do.
What the two human studies found
Only two published human studies tested Ipamorelin. Blood levels in healthy men peaked near 40 minutes, and only half remained in blood roughly 2 hours later [2].
That first study timed the drug; it didn't test strength or healing. The second included 114 patients after bowel surgery [3].
Doctors delivered each dose by vein on two occasions each day, hoping patients could eat solid food sooner. Patients on the drug didn't regain normal bowel use faster than those given a placebo [3].
The small gap between the groups could have been chance. The human record therefore shows timing and a failed patient trial, not better daily health.
The human evidence reviewed here is limited, and the efficacy trial described did not demonstrate a benefit.
What changed in animal bones and body weight
Animal work supplies the numbers used in many sales claims. Adult rats got 18, 90, or 450 micrograms each day for 15 days, and their daily leg-bone growth rose from 42 to 52 microns, or thousandths of a millimeter [4].
The rats' blood didn't show more IGF-1, the liver-made growth protein doctors measured. In 2024, ferrets taking cancer medicine lost roughly 24% less body weight with daily Ipamorelin [5].
IGF-1 stayed level even as rat bones grew faster, which may mean the change happened near the bone. That still doesn't tell you whether the same thing happens in an older person's bones.
The ferret result meant less wasting during harsh cancer treatment, not weight loss for health or looks. Neither animal test proves that a shot will ease your knee or make you stronger.
What Ipamorelin with CJC-1295 does in animal tests
Online shops often mix Ipamorelin with another test drug called CJC-1295. The two drugs reach the gland by separate routes [12].
Ipamorelin causes a quick growth-hormone pulse. CJC-1295 keeps the brain's order to release growth hormone working longer [13], and rats given both had a bigger rise than rats given either one [14].
Scientists call that a combined effect because each drug adds to the other [15]. Sellers use that rat finding to market blended CJC-1295 and Ipamorelin vials.
No human trial has tested that larger rise. Doctors haven't checked the safety of CJC-1295 mixed with Ipamorelin for your heart.
Ipamorelin vs sermorelin: how each tells the gland to act
Ipamorelin and sermorelin both cause a hormone release from the growth gland. They deliver that order in different ways [1].
Sermorelin copies the message sent from the brain to the gland. Ipamorelin copies the hunger message that starts in the stomach; sermorelin once had approval for growth problems in children.
Ipamorelin never gained federal approval and failed its only trial in patients after surgery [3]. Its safety for long-term daily use still hasn't been shown.
Ipamorelin vs tesamorelin: an unapproved drug and an approved one
Tesamorelin is an approved prescription drug, while Ipamorelin isn't. Tesamorelin passed full trials for deep belly fat in one group of patients with unusual fat buildup [1].
Doctors have clear rules for prescribing tesamorelin and know its side effects. Ipamorelin stopped short of long safety tests and failed its only patient trial [3].
That bowel-surgery trial found no useful change in recovery. Online clinics may discuss both drugs, but their medical records aren't alike.
Tesamorelin has results from patients for its approved use. Ipamorelin has no such proof for your health.